| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Crossject Société Anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.93 |
| 52 Week High | €5.76 |
| 52 Week Low | €1.43 |
| Beta | 1.01 |
| 11 Month Change | -13.65% |
| 3 Month Change | 11.56% |
| 1 Year Change | -51.02% |
| 33 Year Change | -36.09% |
| 5 Year Change | -35.02% |
| Change since IPO | -82.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| 74C | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -18.2% | -6.0% | -1.8% |
| 1Y | -51.0% | -3.5% | 13.2% |
Return vs Industry: 74C underperformed the German Medical Equipment industry which returned 0.3% over the past year.
Return vs Market: 74C underperformed the German Market which returned 16.1% over the past year.
Price Volatility
| 74C volatility | |
|---|---|
| 74C Average Weekly Movement | 9.0% |
| Medical Equipment Industry Average Movement | 5.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 74C's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 74C's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 105 | Patrick Alexandre | www.crossject.com |
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, a needle-free device for patient-side management disorders self-injectables. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis.
Crossject Société Anonyme Fundamentals Summary
| 74C fundamental statistics | |
|---|---|
| Market cap | €87.77m |
| Earnings (TTM) | -€10.48m |
| Revenue (TTM) | €2.50m |
35.1x
P/S Ratio-8.4x
P/E RatioIs 74C overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 74C income statement (TTM) | |
|---|---|
| Revenue | €2.50m |
| Cost of Revenue | €10.27m |
| Gross Profit | -€7.77m |
| Other Expenses | €2.71m |
| Earnings | -€10.48m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.24 |
| Gross Margin | -311.09% |
| Net Profit Margin | -419.62% |
| Debt/Equity Ratio | -583.0% |
How did 74C perform over the long term?
See historical performance and comparison